Bayer Sells Carbon Nanotube IP to FutureCarbon

Following its exit from the carbon nanotube sector last year, Bayer MaterialScience (BMS) plans to sell proprietary intellectual property gained in the decade-long research cooperation to one of its former external partners, FutureCarbon, based at Bayreuth, Germany.

As leading provider of carbon-based composites, the Bayer sub-group said the young company will acquire the bulk of the related patents for an undisclosed sum.

The German plastics specialist's work in the field of carbon nanotubes in collaboration with partners focused on complex issues relating to safe production and methods for scaling up the production processes. Next-generation catalysts and new product grades were also developed.

BMS said much of the knowledge has been made available to other companies and research institutions within the Innovation Alliance for Carbon Nanotubes (Inno.CNT), which counts some 90 members.

"We are pleased that FutureCarbon, one of the partners from the Inno.CNT development network, will be carrying on our company's work," said Patrick Thomas, CEO of BMS. "We remain confident that the technology harbors tremendous potential, particularly for a renowned specialist company like FutureCarbon."

Walter Schütz, managing director of the Bayreuth firm, said the Bayer patents will expand its applications base substantially and open up new possibilities and business segments.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.